Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

C. Gerstein, Hertzel; Sattar, Naveed; Rosenstock, Julio; Ramasundarahettige, Chinthanie; E. Pratley, Richard; D. Lópes, Renato; S.P. Lam, Carolyn; S. Khurmi, Nardev; Heenan, Laura; Del Prato, Stefano; Dyal, Leanne; R. Branch, Kelley

doi:10.1056/nejmoa2108269

Public

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

Published in New England Journal of Medicine • Jun 28, 2021

Authors:

Hertzel C. Gerstein

Naveed Sattar

Julio Rosenstock

Abstract

BACKGROUND: Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events among persons with type 2 diabetes. The effect of an exendin-based GLP-1 receptor agonist, efpeglenatide, on cardiovascu...

Subject

Type 2 diabetes

Medicine

Glucagon-like peptide 1 receptor

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!